featured
5 Years vs 2 Years of Adjuvant Bisphosphonate in Patients With Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
JAMA Oncol 2021 Jun 24;[EPub Ahead of Print], TWP Friedl, T Fehm, V Müller, W Lichtenegger, J Blohmer, R Lorenz, H Forstbauer, V Fink, I Bekes, J Huober, J Jückstock, A Schneeweiss, H Tesch, S Mahner, SY Brucker, G Heinrich, L Häberle, PA Fasching, MW Beckmann, RE Coleman, W Janni, B RackFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.